Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. [electronic resource]
Producer: 20130110Description: 2573-80 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Harringtonines -- administration & dosage
- Homoharringtonine
- Humans
- Injections, Subcutaneous
- Leukemia, Myeloid, Chronic-Phase -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Prognosis
- Prospective Studies
- Protein Kinase Inhibitors -- adverse effects
- Salvage Therapy
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.